CELU Stock Price (+0.13) | Stock Quote, Chart & News for Celularity Inc. on Fox Business

Open $1.21	Day Range 1.21 - 1.30
52 Week Range 1.00 - 4.35	Market Cap $34.61M
Shares Outstanding 28.84M	Public Float 13.67M
Beta 0.80	Rev. Per Employee N/A
P/E Ratio N/A	EPS -$3.33
Yield 0.00%	Dividend N/A
EX-DIVIDEND DATE	SHORT INTEREST N/A
AVERAGE VOLUME 33.25K

About celularity inc. - CELU

Celularity, Inc. is a clinical stage biotechnology company, which engages in the development of off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through the following segments: Cell Therapy, BioBanking, Degenerative Disease, and Other. The Cell Therapy segment consists of the therapies the company is researching and developing. The BioBanking segment focuses on stem cells from umbilical cords and placentas and provides storage of such cells on behalf of individuals for future use. The Degenerative Disease segment offers products used in surgical and wound care markets. The company was founded by Robert Joseph Hariri Gordon in 2016 and is headquartered in Florham Park, NJ.

CELU At a Glance

Celularity, Inc.

170 Park Avenue

Florham Park, New Jersey 07932

Phone	1-908-768-2170	Revenue	54.22M
Industry	Miscellaneous Commercial Services	Net Income	-57,892,000.00
Sector	Commercial Services	2024 Sales Growth	138.11%
Fiscal Year-end	12 / 2025	Employees	123
View SEC Filings

CELU Valuation

P/E Current	N/A
P/E Ratio (with extraordinary items)	N/A
P/E Ratio (without extraordinary items)	N/A
Price to Sales Ratio	0.84
Price to Book Ratio	5.307
Price to Cash Flow Ratio	N/A
Enterprise Value to EBITDA	-3.71
Enterprise Value to Sales	2.096
Total Debt to Enterprise Value	0.606

CELU Efficiency

Revenue/Employee	440,813.008
Income Per Employee	-470,666.667
Receivables Turnover	3.999
Total Asset Turnover	0.237

CELU Liquidity

Current Ratio	0.383
Quick Ratio	0.282
Cash Ratio	0.014

CELU Profitability

Gross Margin	57.744
Operating Margin	-71.101
Pretax Margin	-106.772
Net Margin	-106.772
Return on Assets	-25.282
Return on Equity	-232.512
Return on Total Capital	-74.533
Return on Invested Capital	-83.629

CELU Capital Structure

Total Debt to Total Equity	778.952
Total Debt to Total Capital	88.623
Total Debt to Total Assets	21.916
Long-Term Debt to Equity	706.971
Long-Term Debt to Total Capital	80.433

Income Statement
Balance Sheet
Cash Flow Statement

Annual Financials for Celularity Inc. - CELU

Collapse All in section

All values USD millions.	2021	2022	2023	2024	5-year trend
Sales/Revenue	21.34M	17.98M	22.77M	54.22M
Sales Growth	-	-15.75%	+26.68%	+138.11%
Cost of Goods Sold (COGS) incl D&A	18.47M	29.10M	25.34M	22.91M
COGS excluding D&A	-	-	-	-	-
Depreciation & Amortization Expense	8.82M	9.38M	9.32M	7.92M
Depreciation	6.63M	7.18M	7.13M	6.17M
Amortization of Intangibles	2.19M	2.19M	2.19M	1.75M
COGS Growth	-	+57.56%	-12.92%	-9.59%
Gross Income	2.87M	(11.13M)	(2.57M)	31.31M
Gross Income Growth	-	-488.34%	+76.91%	+1,318.72%
Gross Profit Margin	+13.43%	-61.90%	-11.28%	+57.74%

	2021	2022	2023	2024	5-year trend
SG&A Expense	153.07M	137.14M	73.91M	69.86M
Research & Development	81.73M	71.12M	23.33M	11.22M
Other SG&A	71.34M	66.02M	50.58M	58.64M
SGA Growth	+3,527.26%	-10.41%	-46.11%	-5.48%
Other Operating Expense	-	-	-	-	-
Unusual Expense	(54.63M)	(162.07M)	110.82M	3.81M
EBIT after Unusual Expense	(95.58M)	13.80M	(187.30M)	(42.36M)
Non Operating Income/Expense	(1.35M)	404.00K	(5.97M)	(9.27M)
Non-Operating Interest Income	332.00K	365.00K	320.00K	331.00K
Equity in Earnings of Affiliates	-	-	-	-	-
Interest Expense	-	3.17M	3.02M	6.26M
Interest Expense Growth	-	-	-	+107.76%	-
Gross Interest Expense	-	3.17M	3.02M	6.26M
Interest Capitalized	-	-	-	-	-
Pretax Income	(100.10M)	14.21M	(196.28M)	(57.89M)
Pretax Income Growth	-104.00%	+114.19%	-1,481.80%	+70.51%
Pretax Margin	-469.17%	+79.03%	-862.00%	-106.77%
Income Tax	-	20.00K	13.00K	10.00K
Income Tax - Current - Domestic	-	17.00K	13.00K	10.00K
Income Tax - Current - Foreign	-	-	-	-	-
Income Tax - Deferred - Domestic	-	-	-	3.00K	-
Income Tax - Deferred - Foreign	-	-	-	-	-
Income Tax Credits	-	-	-	-	-
Equity in Earnings of Affiliates	-	-	-	-	-
Other After Tax Income (Expense)	-	-	-	-	-
Consolidated Net Income	(100.12M)	14.19M	(196.29M)	(57.89M)
Minority Interest Expense	-	-	-	-	-
Net Income	(100.12M)	14.19M	(196.29M)	(57.89M)
Net Income Growth	-103.24%	+114.18%	-1,483.14%	+70.51%
Net Margin Growth	-469.27%	+78.95%	-862.04%	-106.77%
Extraordinaries & Discontinued Operations	-	-	-	-	-
Discontinued Operations	-	-	-	-	-
Net Income After Extraordinaries	(100.12M)	14.19M	(196.29M)	(57.89M)
Preferred Dividends	-	-	-	-	-
Net Income Available to Common	(100.12M)	14.19M	(196.29M)	(57.89M)
EPS (Basic)	-14.9302	1.0144	-11.0197	-2.6446
EPS (Basic) Growth	-8.92%	+106.79%	-1,186.33%	+76.00%
Basic Shares Outstanding	6.71M	13.99M	17.81M	21.89M
EPS (Diluted)	-14.9302	0.9472	-11.0197	-2.6446
EPS (Diluted) Growth	-8.92%	+106.34%	-1,263.40%	+76.00%
Diluted Shares Outstanding	6.71M	14.98M	17.81M	21.89M
EBITDA	(141.39M)	(138.89M)	(67.16M)	(30.63M)
EBITDA Growth	-3,250.43%	+1.77%	+51.65%	+54.39%
EBITDA Margin	-662.70%	-772.68%	-294.91%	-56.49%

Filing Date	Type	Category	Amended
No results

Insider Actions for Celularity Inc. - CELU

Date	Name	Shares	Transaction	Value
Jan 16, 2026	Vincent LeVien Director	153,847	Grant, award or other acq pursuant to Rule 16b-3(d)	0.00
Jan 16, 2026	Shiu Fei Ling Director	256,026	Grant, award or other acq pursuant to Rule 16b-3(d)	0.00
Jan 16, 2026	Diane L. Parks Director	520,021	Grant, award or other acq pursuant to Rule 16b-3(d)	0.00
Jan 16, 2026	Peter H. Diamandis Director	394,150	Grant, award or other acq pursuant to Rule 16b-3(d)	0.00
Jul 29, 2025	Genting Bhd.	300,000	Other acquisition or disposition	0.00
Jul 29, 2025	Kok Thay Lim	3,700,000	Other acquisition or disposition	0.00
Jul 29, 2025	Genting Bhd.	500,000	Other acquisition or disposition	0.00
Jul 29, 2025	Genting Bhd.	1,350,000	Other acquisition or disposition	0.00
Jul 29, 2025	Genting Bhd.	N/A	Other acquisition or disposition	0.00
Jul 29, 2025	Genting Bhd.	300,000	Other acquisition or disposition	0.00
Jul 29, 2025	Genting Bhd.	N/A	Other acquisition or disposition	0.00
Jul 29, 2025	Genting Bhd.	N/A	Other acquisition or disposition	0.00
Feb 20, 2025	David C. Beers Chief Financial Officer	21,932	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	0.00
Feb 20, 2025	David C. Beers Chief Financial Officer	17,536	Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.14 per share	37,527.04
Feb 20, 2025	David C. Beers Chief Financial Officer	N/A	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	0.00
Feb 20, 2025	John R. Haines Senior Exec Vice President	35,092	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	0.00
Feb 20, 2025	John R. Haines Senior Exec Vice President	28,057	Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.14 per share	60,041.98
Feb 20, 2025	John R. Haines Senior Exec Vice President	N/A	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	0.00
Feb 20, 2025	Stephen A. Brigido Pres., Functional Regeneration	11,641	Exercise or conversion of derivative security exempted pursuant to Rule 16b-3	0.00
Feb 20, 2025	Stephen A. Brigido Pres., Functional Regeneration	8,369	Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $2.14 per share	17,909.66

1 Week		6.56%
1 Month		0.00%
3 Months		-26.97%
1 Year		-39.81%
5 Years		-98.73%

celularity inc. - CELU

CELU

Company Overview: celularity inc. - CELU

CELU Key Data

CELU Performance

CELU Analyst Ratings